PHAR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast PHAR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHAR is 39.50 USD with a low forecast of 37.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

37.00

Averages

39.50

High

42.00

Current: 0.000

Low

37.00

Averages

39.50

High

42.00

Guggenheim

Debjit Chattopadhyay

Buy

maintain

$32 -> $39

2025-12-04

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$32 -> $39

2025-12-04

maintain

Buy

Reason

Guggenheim analyst Debjit Chattopadhyay raised the firm's price target on Pharvaris to $39 from $32 and keeps a Buy rating on the shares after the company shared that its RAPIDe-3 trial hit on the primary and all 11 secondary endpoints. Post the RAPIDe-3 topline data readout, the firm is increasing its global peak sales estimate for deucrictibant to $1.65B from $1.4B during 2037.

Oppenheimer

Outperform

maintain

$41 -> $42

2025-11-07

Reason

Oppenheimer

Price Target

$41 -> $42

2025-11-07

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Pharming to $42 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 results with $97M in sales, meaningfully above its estimates and generally in line with consensus of $90M/$98M, respectively.

Oppenheimer

Jeff Jones

Outperform

maintain

$40 -> $41

2025-08-01

Reason

Oppenheimer

Jeff Jones

Price Target

$40 -> $41

2025-08-01

maintain

Outperform

Reason

Oppenheimer analyst Jeff Jones raised the firm's price target on Pharming to $41 from $40 and keeps an Outperform rating on the shares after the company announced Q2 results. Moving into the second half of 2025, Oppenheimer anticipates competitive pressure on Ruconest from Ekterly, potentially up to a 20% hit by year-end 2026 as patients try the oral option, its estimates counterbalanced by reduced expenses.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$37

2025-03-21

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37

2025-03-21

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$37

2025-03-20

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37

2025-03-20

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$37

2025-03-14

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37

2025-03-14

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Pharming Group NV (PHAR.O) is 337.40, compared to its 5-year average forward P/E of -53.58. For a more detailed relative valuation and DCF analysis to assess Pharming Group NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-53.58

Current PE

337.40

Overvalued PE

217.56

Undervalued PE

-324.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

143.25

Current EV/EBITDA

51.96

Overvalued EV/EBITDA

402.66

Undervalued EV/EBITDA

-116.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.76

Current PS

3.03

Overvalued PS

3.38

Undervalued PS

2.14

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PHAR News & Events

Events Timeline

No data

News

9.5

01-08Globenewswire

PinnedPharming Reports $376 Million Revenue for 2025, Exceeding Guidance by 27%

9.5

01-08NASDAQ.COM

Pharming Reports $376M Preliminary 2025 Revenue, Exceeding Guidance by 27%

9.0

2025-12-30NASDAQ.COM

FDA Approves First CAR T-Cell Therapy and Digital Health Pilot

People Also Watch

Frequently Asked Questions

What is Pharming Group NV (PHAR) stock price today?

The current price of PHAR is 18.7196 USD — it has increased 4.64 % in the last trading day.

What is Pharming Group NV (PHAR)'s business?

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

What is the price predicton of PHAR Stock?

What is Pharming Group NV (PHAR)'s revenue for the last quarter?

Pharming Group NV revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Pharming Group NV (PHAR)'s earnings per share (EPS) for the last quarter?

Pharming Group NV. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Pharming Group NV (PHAR)'s fundamentals?

The market is revising Upward the revenue expectations for Pharming Group N.V. (PHAR) for FY2025, with the revenue forecasts being adjusted by 2.24% over the past three months. During the same period, the stock price has changed by 28.33%.

How many employees does Pharming Group NV (PHAR). have?

Pharming Group NV (PHAR) has 382 emplpoyees as of January 09 2026.

What is Pharming Group NV (PHAR) market cap?

Today PHAR has the market capitalization of 1.25B USD.